Fred Kurland - Net Worth and Insider Trading

Fred Kurland Net Worth

The estimated net worth of Fred Kurland is at least $447,000 dollars as of 2024-11-10. Fred Kurland is the CFO of Corcept Therapeutics Inc and owns about 7,500 shares of Corcept Therapeutics Inc (CORT) stock worth over $447,000. Details can be seen in Fred Kurland's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Fred Kurland has not made any transactions after 2005-12-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Fred Kurland

Fred Kurland Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Fred Kurland owns 5 companies in total, including Aridis Pharmaceuticals Inc (ARDS) , XOMA Royalty Corp (XOMA) , and Corcept Therapeutics Inc (CORT) among others .

Click here to see the complete history of Fred Kurland’s form 4 insider trades.

Insider Ownership Summary of Fred Kurland

Ticker	Comapny	Transaction Date	Type of Owner
ARDS	Aridis Pharmaceuticals Inc	2018-08-13	Chief Financial Officer
XOMA	XOMA Royalty Corp	2013-11-13	CFO & VP Finance
CORT	Corcept Therapeutics Inc	2005-12-20	Chief Financial Officer
		2003-10-28	CFO
		2013-11-13	CFO & VP Finance

Fred Kurland Latest Holdings Summary

Fred Kurland currently owns a total of 1 stock. Fred Kurland owns 7,500 shares of Corcept Therapeutics Inc (CORT) as of December 20, 2005, with a value of $447,000.

Latest Holdings of Fred Kurland

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CORT	Corcept Therapeutics Inc	2005-12-20	7,500	59.60	447,000

Holding Weightings of Fred Kurland

Fred Kurland Form 4 Trading Tracker

According to the SEC Form 4 filings, Fred Kurland has made a total of 0 transactions in Corcept Therapeutics Inc (CORT) over the past 5 years. The most-recent trade in Corcept Therapeutics Inc is the acquisition of 2,500 shares on December 20, 2005, which cost Fred Kurland around $10,375.

Insider Trading History of Fred Kurland

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Fred Kurland Trading Performance

GuruFocus tracks the stock performance after each of Fred Kurland's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Fred Kurland is 19.82%. GuruFocus also compares Fred Kurland's trading performance to market benchmark return within the same time period. The performance of stocks bought by Fred Kurland within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Fred Kurland's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Fred Kurland

Average Return

Average return per transaction

Outperforming Transactions

1 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	31.21
Relative Return to S&P 500(%)	29.65

Fred Kurland Ownership Network

Ownership Network List of Fred Kurland

No Data

Ownership Network Relation of Fred Kurland

Fred Kurland Owned Company Details

What does Aridis Pharmaceuticals Inc do?

Who are the key executives at Aridis Pharmaceuticals Inc?

Fred Kurland is the Chief Financial Officer of Aridis Pharmaceuticals Inc. Other key executives at Aridis Pharmaceuticals Inc include director & 10 percent owner & CEO & CSO & Director Vu Truong , director & 10 percent owner Eric Patzer , and 10 percent owner Fibrosis Foundation Cystic .

Aridis Pharmaceuticals Inc (ARDS) Insider Trades Summary

Over the past 18 months, Fred Kurland made no insider transaction in Aridis Pharmaceuticals Inc (ARDS). Other recent insider transactions involving Aridis Pharmaceuticals Inc (ARDS) include a net purchase of 714,286 shares made by Eric Patzer , and a net purchase of 714,286 shares made by Vu Truong .

In summary, during the past 3 months, insiders sold 0 shares of Aridis Pharmaceuticals Inc (ARDS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aridis Pharmaceuticals Inc (ARDS) were sold and 1,428,572 shares were bought by its insiders, resulting in a net purchase of 1,428,572 shares.

Aridis Pharmaceuticals Inc (ARDS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aridis Pharmaceuticals Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

Fred Kurland is the CFO & VP Finance of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, Fred Kurland made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , and a net purchase of 5,500 shares made by Owen Hughes .

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Corcept Therapeutics Inc do?

Who are the key executives at Corcept Therapeutics Inc?

Fred Kurland is the Chief Financial Officer of Corcept Therapeutics Inc. Other key executives at Corcept Therapeutics Inc include Chief Development Officer William Guyer , CHIEF FINANCIAL OFFICER Gary Charles Robb , and Chief Accounting Officer Joseph Douglas Lyon .

Corcept Therapeutics Inc (CORT) Insider Trades Summary

Over the past 18 months, Fred Kurland made no insider transaction in Corcept Therapeutics Inc (CORT). Other recent insider transactions involving Corcept Therapeutics Inc (CORT) include a net sale of 70,000 shares made by Joseph Douglas Lyon , a net sale of 28,750 shares made by Swisher Daniel N Jr , and a net sale of 225,000 shares made by Sean Maduck .

In summary, during the past 3 months, insiders sold 44,101 shares of Corcept Therapeutics Inc (CORT) in total and bought 0 shares, with a net sale of 44,101 shares. During the past 18 months, 517,899 shares of Corcept Therapeutics Inc (CORT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 517,899 shares.

Corcept Therapeutics Inc (CORT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corcept Therapeutics Inc Insider Transactions

No Available Data

What does Genitope Corp do?

Who are the key executives at Genitope Corp?

Fred Kurland is the CFO of Genitope Corp. Other key executives at Genitope Corp include other: Former 10% Owner Cpmg Inc , Controller/Principl Acctg Off Gregory L Overholtzer , and 10 percent owner Rose Edward R Iii .

Genitope Corp (GTOPQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genitope Corp (GTOPQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genitope Corp (GTOPQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genitope Corp (GTOPQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genitope Corp Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

Fred Kurland Mailing Address

Above is the net worth, insider trading, and ownership report for Fred Kurland. You might contact Fred Kurland via mailing address: C/o Genitope Corp, 525 Penobscot Drive, Redwood City Ca 94063.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.